Publicaciones científicas

Local delivery of optimized nanobodies targeting the PD-1/PD-L1 axis with a self-amplifying RNA viral vector induces potent antitumor responses

01-may-2023 | Revista: Cancer Letters

Noelia Silva-Pilipich 1, Ester Blanco 2, Teresa Lozano 3, Eva Martisova 1, Ana Igea 1, Guillermo Herrador-Cañete 1, María Cristina Ballesteros-Briones 1, Marta Gorraiz 3, Patricia Sarrión 3, Gualberto González-Sapienza 4, Juan José Lasarte 3, Lucía Vanrell 5, Cristian Smerdou 6


Despite the success of immune checkpoint blockade for cancer therapy, many patients do not respond adequately. We aimed to improve this therapy by optimizing both the antibodies and their delivery route, using small monodomain antibodies (nanobodies) delivered locally with a self-amplifying RNA (saRNA) vector based on Semliki Forest virus (SFV).

We generated nanobodies against PD-1 and PD-L1 able to inhibit both human and mouse interactions. Incorporation of a dimerization domain reduced PD-1/PD-L1 IC50 by 8- and 40-fold for anti-PD-L1 and anti-PD-1 nanobodies, respectively. SFV viral particles expressing dimeric nanobodies showed a potent antitumor response in the MC38 model, resulting in >50% complete regressions, and showed better therapeutic efficacy compared to vectors expressing conventional antibodies.

These effects were also observed in the B16 melanoma model. Although a short-term expression of nanobodies was observed due to the cytopathic nature of the saRNA vector, it was enough to generate a strong proinflammatory response in tumors, increasing infiltration of NK and CD8+ T cells. Delivery of the SFV vector expressing dimeric nanobodies by local plasmid electroporation, which could be more easily translated to the clinic, also showed a potent antitumor effect.

CITA DEL ARTÍCULO Cancer Lett. 2023 May 1:561:216139. doi: 10.1016/j.canlet.2023.216139. Epub 2023 Mar 29.